Xtant Medical Holdings, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers events occurring at the Annual Meeting of Stockholders held on November 7, 2025. The filing details the results of five stockholder proposals and the approval of an amendment to the company's equity incentive plan.
Key Financial Metrics
This filing is a corporate governance report and does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. No financial statements are included in this document.
Material Changes and Corporate Actions
- Equity Plan Amendment: Stockholders approved an amendment to the 2023 Equity Incentive Plan, increasing the number of shares available for issuance by 12,300,000 shares. The amendment became effective immediately.
- Board Elections: All six nominees proposed by the Board of Directors were elected. Voting results showed strong support, with "Votes For" ranging from approximately 79.0 million to 79.8 million per nominee.
- Auditor Ratification: Stockholders ratified the appointment of Grant Thornton LLP as the independent registered public accounting firm for the year ending December 31, 2025.
- Executive Compensation: Stockholders approved the advisory vote on executive compensation ("Say-on-Pay") and voted to conduct future advisory votes on an annual basis.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding future financial guidance, operational outlook, or specific risk factors. The document focuses solely on the administrative results of the Annual Meeting.
Investor Verification Checklist
- Verify the impact of the 12,300,000 share increase on potential future dilution by reviewing the full text of the Amended and Restated 2023 Equity Incentive Plan (Exhibit 10.1).
- Confirm the total number of shares outstanding (140,000,485 as of the September 9, 2025 record date) against subsequent filings for any changes.
- Review the 2025 Proxy Statement (filed September 15, 2025) for detailed descriptions of the director nominees and executive compensation packages referenced in the voting results.
- Note that the company is not an emerging growth company and trades on the NYSE American under the symbol XTNT.